Tag: patent cliff

How can a huge global company simplify its operations? AstraZeneca, a 60,000-employee pharmaceutical giant, faced a “patent cliff” starting around 2012, and saw revenue and income fall sharply for several years running. <ClickHere>

The world’s biggest pharmaceutical companies have said they will work together to try to find treatments and a vaccine to tackle the coronavirus pandemic that is sweeping the world. <ClickHere>

Japanese infectious disease specialist Shionogi & Co. Ltd. said it will partner with Chinese insurance giant Ping An to establish a data-driven joint venture to develop new drugs in a deal involving ¥‎33.53 billion (US$311 million. <ClickHere> 

Over the next five years, biotechnology copycats will steal market share away from blockbuster drugs made by such major pharmaceutical companies. <ClickHere> 

Over the last decade the pharmaceutical industry has seen many of its blockbuster products come off patent in therapy areas such as cardiovascular, diabetes and respiratory. <ClickHere> 

With some of the world’s best-known biologics continuing to face patent expiration in the coming years, the biosimilars market is set for continued growth. <ClickHere>

According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. <ClickHere>

The coronavirus outbreak is bringing attention to the fast-growing vaccine industry. The vaccine market has grown sixfold over the past two decades, worth more than $35 billion today, according to AB Bernstein. <ClickHere> 

Sanofi is now back to the market’s attention mainly because of its efforts in tackling the Covid-19 pandemic. <ClickHere> 

Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. <ClickHere>